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Abstract
Introduction: Glycolytic activity and hypoxia are associated with poor prognosis and radiation resistance. Including
both the tumor uptake of 2-deoxy-2-[18 F]-fluorodeoxyglucose (FDG) and the proposed hypoxia tracer copper(II)diacetyl-
bis(N4)-methylsemithio-carbazone (Cu-ATSM) in targeted therapy planning may therefore lead to improved tumor
control. In this study we analyzed the overlap between sub-volumes of FDG and hypoxia assessed by the uptake
of 64Cu-ATSM in canine solid tumors, and evaluated the possibilities for dose redistribution within the gross tumor
volume (GTV).
Materials and methods: Positron emission tomography/computed tomography (PET/CT) scans of five spontaneous
canine solid tumors were included. FDG-PET/CT was obtained at day 1, 64Cu-ATSM at day 2 and 3 (3 and 24 h pi.). GTV
was delineated and CT images were co-registered. Sub-volumes for 3 h and 24 h 64Cu-ATSM (Cu3 and Cu24) were
defined by a threshold based method. FDG sub-volumes were delineated at 40% (FDG40) and 50% (FDG50) of
SUVmax. The size of sub-volumes, intersection and biological target volume (BTV) were measured in a treatment
planning software. By varying the average dose prescription to the tumor from 66 to 85 Gy, the possible dose
boost (DB) was calculated for the three scenarios that the optimal target for the boost was one, the union or the
intersection of the FDG and 64Cu-ATSM sub-volumes.
Results: The potential boost volumes represented a fairly large fraction of the total GTV: Cu3 49.8% (26.8-72.5%),
Cu24 28.1% (2.4-54.3%), FDG40 45.2% (10.1-75.2%), and FDG50 32.5% (2.6-68.1%). A BTV including the union (∪) of
Cu3 and FDG would involve boosting to a larger fraction of the GTV, in the case of Cu3∪FDG40 63.5% (51.8-83.8)
and Cu3∪FDG50 48.1% (43.7-80.8). The union allowed only a very limited DB whereas the intersection allowed a
substantial dose escalation.
Conclusions: FDG and 64Cu-ATSM sub-volumes were only partly overlapping, suggesting that the tracers offer
complementing information on tumor physiology. Targeting the combined PET positive volume (BTV) for dose
escalation within the GTV results in a limited DB. This suggests a more refined dose redistribution based on a
weighted combination of the PET tracers in order to obtain an improved tumor control.
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Introduction
Intensity-modulated radiotherapy (IMRT) has allowed for
more complex dose distributions. One of the challenges
in radiation oncology research is to determine the thera-
peutic potential of advanced imaging combined with
non-uniform and very accurate dose delivery [1].
In conventional radiotherapy (RT) the dose is delivered
homogeneously to the target volume. However, solid
tumors are often very heterogeneous with a regionally
variable radiosensitivity, and the tumor control might
therefore be increased with a non-uniform dose distri-
bution [2]. It is hypothesized that a redistribution of the
dose can potentially increase the tumor control probability
(TCP) without increasing radiation toxicity [2-4].
Positron emission tomography (PET) can provide spatial
information on tumor characteristics associated with
radioresistance, and including this modality in RT plan-
ning would allow a more refined characterization of
individual tumors and thereby a tailored prescription
of radiation dose [2]. In 2000, Ling et al. proposed the
concept of combining biological images (e.g. PET with
multiple tracers) and thereby targeting the union of differ-
ent sub-volumes, in a “biological target volume” (BTV) [5].
Bentzen has introduced the concept of theragnostic
imaging, referring to the use of information from func-
tional and molecular imaging to determine individual
treatment of patients [1]. The successful clinical intro-
duction of this concept depends on the ability of the
diagnostic method to visualize tumor sub-volumes that
are potentially radioresistant, e.g. hypoxic areas, and the
ability of delivery methods to apply a higher dose to that
specific volume. The aim of such “dose painting” is
reaching biological conformity of the dose delivery to
tumor. In dose painting by contours (DPBC) a higher,
homogenous dose is prescribed to the functional part of
the gross tumor volume (GTV) delineated on computed
tomography (CT) and thereby distinguishing high-risk
from low-risk areas [6]. This strategy is clinically feas-
ible as commercial treatment planning software can be
used and uncertainties can be accounted for by addition
of margins [7]. Dose painting by numbers (DPBN) is a
more sophisticated strategy where the dose prescription
is based on information from every voxel [1,8]. Both
dose painting strategies can be used to substantially in-
crease the dose to specific regions in the tumor. How-
ever, by using the DPBN approach, a higher peak dose
can be obtained, which might have a positive impact on
TCP [7].
A large boost volume may limit the option for escalation
to a high peak dose due to normal tissue constraints. Tar-
geting a BTV, defined by the DPBC strategy, will inevitably
lead to a larger boost volume than targeting a sub-volume
based on one PET tracer, and potentially thereby limit the
possibility for dose redistribution. The inclusion of more
radioresistant regions for RT, can therefore possibly lead
to a decreased tumor control.
Glycolytic activity and hypoxia are examples of bio-
logic targets for RT treatment since they are both associ-
ated with a malignant phenotype and poor prognosis
[9-12]. Hypoxia upregulates numerous glycolytic genes
and 2-deoxy-2-[18 F]-fluorodeoxyglucose (FDG) has there-
fore been suggested has as a marker of tumor hypoxia
[13]. However, several promising hypoxia specific en-
dogenous markers and PET tracers have been intro-
duced, and it can be hypothesized that including the
uptake of both FDG and a hypoxia tracer in targeted
therapy may lead to an improved TCP. The correlation
between FDG uptake and hypoxia markers has been ex-
tensively studied, but the results have been inconsistent
and generally failed to consistently link a high uptake of
FDG with tumor hypoxia [14-18]. The most recent
studies have evaluated the spatial correlation between
FDG and hypoxia tracers by using isolated tumor cell lines,
two-dimensional pixel-by-pixel comparisons of either
autoradiography or PET based images, some with
microscopic validation [13-16,19,20].
The overall conclusion seems to be that FDG is not a
good marker of hypoxia, but that both FDG and hypoxia
tracers can provide useful, possibly complementary, in-
formation regarding prognosis. These studies provide
valuable information on tracer uptake and tumor micro-
environment. However, a more pragmatic approach on
integrating this information in RT planning has not been
explored. Translating a voxel-based PET signal into a
threshold-based RT target volume might impact the
correlation between tracers. Therefore, the question is
whether the observed mismatches between FDG uptake
and hypoxia in the studies mentioned above also make
FDG a poor marker of hypoxia in threshold-based RT
planning.
In this study we analyzed the correlation between the PET
positive sub-volumes of FDG and the hypoxia tracer copper
(II)diacetyl-bis(N4)-methylsemithiocarbazone (Cu-ATSM) at
two different time-points after injection in spontaneous
canine tumors.
Using a threshold based method for target definition
introduces several uncertainties and might impact the
results. Various cut-off values for FDG uptake have previ-
ously been used, but the ideal cut-off has not been defined.
64Cu-ATSM is a rather novel hypoxia tracer, and the dis-
tribution kinetics and image acquisition time is not com-
pletely clarified. In order to investigate these aspects, we
included different cut-off values for FDG and two different
time-points for 64Cu-ATSM imaging in this analysis.
The aim of this study was to evaluate FDG as a marker
of hypoxia in a DPBC approach, and to assess the feasi-
bility for redistribution of dose by a DPBC strategy that
includes the PET tracers FDG and 64Cu-ATSM.
Clausen et al. Radiation Oncology 2013, 8:262 Page 2 of 9
http://www.ro-journal.com/content/8/1/262
Methods and materials
Tumor imaging and image processing
This study was based on PET/CT scans of five spontaneous
canine sarcomas and carcinomas. Subjects were scanned
prior to and as part of the planning of subsequent radi-
ation therapy, and according to a prospective protocol
approved by the local ethics committee [21]. PET/CT
images were obtained using a combined PET/CT scanner
(Biograph 40, Siemens, Munich, Germany), consisting of a
high-resolution PET-scanner and a 40-slice CT-scanner.
The CT scanning parameters were: slice thickness of
3.0 mm, 120 kV, 170 mAs, pitch 1.2, collimation 24 ×
1.2 mm and a B30 kernel. The PET images were ac-
quired using a 3D acquisition mode and a 3D OSEM
reconstruction algorithm with sections of 8 subsets and 4
iterations and smoothed using a Gaussian filter with
3-mm FWHM, and a matrix size of 256 × 256.
The dogs were scanned on three consecutive days,
18 F-FDG at day 1 (approx. 1 hour p.i.) and 64Cu-ATSM
at day 2 and 3 (approx. 3 and 24 hours pi.). This scan-
ning protocol allowed sufficient radioactive decay and
tracer washout between imaging sessions with the two
tracers. Dogs received a mean activity of 7.7 MBq/kg of
both tracers.
Tumor and sub-volume delineation
All scans were transferred to a radiotherapy treatment
planning software, Eclipse v10 (Varian Medical Systems,
Palo Alto, CA, US). The GTV was delineated on the day
1 CT in collaboration with an experienced radiologist and
a veterinarian. CT images were manually co-registered in
a treatment planning software image registration (Eclipse,
Varian Medical Systems, Palo Alto, US) with the day 2
CT-scan as the reference image. The PET uptake was used
to define glycolytic and hypoxic sub-volumes. The hypoxic
sub-volume was defined based on a study performed by
Bowen et al. [22], who developed transformation function
curves between 3 h 64Cu-ATSM uptake and tissue oxygen
tension. The SUV that reflected tumor hypoxia (defined
as pO2 < 10 mmHg) was 1.4. This cut-off value was used
to define the hypoxic sub-volume for the 3 h 64Cu-ATSM
in this study (Cu3). No previous studies have investigated
a cut-off value for the uptake of 64Cu-ATSM 24 h
p.i., and the 24 h 64Cu-ATSM sub-volume (Cu24) was
therefore defined based on calculation of the corre-
sponding tumor-to-muscle ratio (T/M), which was as-
sumed constant.
Based on previous studies, two FDG sub-volumes were
delineated at 40% (FDG40) and 50% (FDG50) of SUVmax
[23,24]. Boolean operators function was used to measure
all sub-volumes including the intersection of the sub-
volumes and the total BTV defined as the union of
64Cu-ATSM and either FDG40 or FDG50.
Dose redistribution
One strategy for dose redistribution is to use pre-
treatment PET data to increase the dose in potentially
radioresistant areas. We explored this strategy assuming
that: 1) the volumes are best selected using a DPBC ap-
proach by a cut-off value 2) the integral dose to the
GTV is kept constant which would tend to keep toxicity
at a proximity constant level, and 3) a “base dose” of
66 Gy to the CT-defined tumor needs to be maintained
in order to obtain tumor control. In reality, the dose
distribution within the GTV will also affect the sur-
rounding normal tissue [25]. Situations may occur where a
high dose region is present in the periphery of the GTV,
and this can be problematic in cases where a serial
responding organ is closely related to the GTV. In a
clinical setting dose constraints would be applied for or-
gans at risk.
By varying the average dose prescription (P) to the
tumor from 66 Gy to 85 Gy, the possible dose increase
(“boost dose”, DB) upholding the assumptions 1–3 above
for one or multiple PET tracers can be calculated. An
average GTV dose above 85 Gy is probably unwarranted
in most clinical scenarios and was therefore used as the
upper limit in this work. The boost increase is derived
assuming that the optimal target for boost dose equals
one of, the union of or the intersection of the PET tracers,
using the volumetric data for the PET tracers (Vi) and the
total GTV.
It follows from assumptions 1–3 that
P ¼ DB x Vi=GTVð Þ þ 66 x 1−Vi=GTVð Þ
The ratio (R) of dose increase (“boost ratio”) is thus
R ¼ DB=P ¼ P–66 x 1−Vi=GTVð Þð Þ= P x Vi=GTVð Þ
Results
The SUVmax measurements for FDG PET and
64Cu-ATSM
PET ranged from 7.9-23.1 (FDG) and 2.3-3.6 (Cu3). The
cut-off value of SUV 1.4 defining the Cu3 sub-volume
in this study corresponded to 50% of SUVmax. PET/CT
images and the sub-volumes delineated are depicted in
Figure 1 for all five cases. All defined sub-volumes were
measured by volume and their fraction of the total GTV
was calculated. The overlap or intersection between
FDG and 64Cu-ATSM was described by the intersection
volume (∩), which is the volume included in both tracer
sub-volumes. The union (∪) of both tracers representing
the BTV was also measured. The patient characteristics
and sub-volume data are outlined in Table 1.
The potential boost volumes represent a fairly large
fraction of the total GTV: Cu3 49.8% (26.8-72.5%), Cu24
28.1% (2.4-54.3%), FDG40 45.2% (10.1-75.2%), and FDG50
32.5% (2.6-68.1%). Figure 2 shows the fraction of GTV for
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all sub-volumes and illustrates the large variation between
the cases. The mean values and proportional PET positive
volume of FDG40, Cu3 and Cu24, and their respective
overlap is shown in Figure 3A. Figure 3B shows the over-
lap between FDG50 and the two Cu-ATSM sub-volumes.
The data reflects a general trend that a large propor-
tion of Cu24 is included in either Cu3 or FDG. Cu24
is included in the Cu3∪FDG40 BTV in three out of
five cases, whereas the Cu3∪FDG50 BTV encompasses
Cu24 in two cases. On average, 3.5% of the Cu24 sub-
volume is not included in the Cu3∪FDG40 BTV, and
the Cu3∪FDG50 BTV does not encompass 5.2% of Cu24.
Only in one patient the Cu24 sub-volume is larger than
that of Cu3.
In the following, only the relationship between Cu3
and the two FDG sub-volumes, FDG40 and FDG50, is
analyzed.
Cu3∩FDG40 covered 72.3% (46.6-98.5%) of the FDG40
volume and 66.7% (14.9-88.4%) of the Cu3 volume. The
Cu3∩FDG50 covered 78.2% (52.8-98.2%) of FDG50
and 52.3% (3.9-82.8%) of Cu3.
A BTV based on the chosen cut-off values for Cu3
and FDG involves boosting to a large fraction of the total
GTV, in the case of Cu3∪FDG40 that fraction is 63.5%
(51.8-83.8) and for Cu3∪FDG50 48.1% (43.7-80.8). The
BTV allows only a very limited DB whereas the intersec-
tion, which is a smaller volume, allows a substantial
dose escalation. Figure 4 shows the possible dose escal-
ation to sub-volumes when varying the average prescribed
dose to the GTV.
Discussion
In this study, tumor sub-volumes were defined based on
a DPBC strategy of FDG and 64Cu-ATSM PET, and the
overlap between these sub-volumes was analyzed.
Two cut-off values for FDG uptake were explored, and
64Cu-ATSM uptake was analyzed by sub-volumes based
on two different time-points for image acquisition. We
Figure 1 Tracer uptake, distribution and sub-volume definition. The dogs are horizontally listed 1–5. The images in column A show the tumor
location and GTV (pink). B: FDG40 (red) and FDG50 (black), C: Cu3 (green), D: Cu24 (blue). Column E shows all sub-volumes and their respective
overlap. The tendency of the Cu24 sub-volume to be included in either the FDG sub-volume or Cu3 is illustrated here.
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Table 1 Patient characteristics and sub-volume data
Dog no. Tumor type Tumor
localization
GTV
(ccm)
FDG40
(ccm)
FDG50
(ccm)
Cu3
(ccm)
Cu24
(ccm)
Cu3∪FDG40
(ccm)
Cu3∪FDG50
(ccm)
Cu3∩FDG40/FDG40
(%)
Cu3∩FDG40/Cu3
(%)
Cu3∩FDG50/FDG50
(%)
Cu3∩FDG50/Cu3
(%)
1 Hemangiopericytoma Lumbar
region
128.7 13.0 3.4 85.8 61.6 86.1 85.9 98.5 14.9 98.2 3.9
2 Fibrosarcoma Lat. cervical
region
88.2 66.4 60.1 63.9 17.0 73.9 71.3 84.7 88.4 88.2 82.8
3 Squamous cell
carcinoma
Nasal cavity 55.4 23.7 17.0 21.2 30.0 28.7 25.4 68.9 76.9 76.4 61.0
4 Adenocarcinoma Nasopharynx 20.8 10.3 5.3 9.3 3.5 13.0 10.7 62.9 69.3 75.4 42.8
5 Undiff. soft tissue
sarcoma
Mandible 23.2 11.2 8.4 6.2 0.6 12.2 10.2 46.6 83.9 52.8 70.8
Avg. 63.3 24.9 18.8 37.3 22.5 42.8 40.7 72.3 66.7 78.2 52.3
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Figure 2 Sub-volume fraction of the total GTV for 64Cu-ATSM (Cu3), FDG40 and FDG50.
Figure 3 The proportional PET positive volume of FDG40, Cu3 and Cu24, and their respective overlap is shown in A. B shows the overlap
between FDG50 and the two 64Cu-ATSM sub-volumes. The areas and the overlap drawn schematically correspond to the average volumetric
size (% of GTV) found in the study.
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observed an overlap between all 64Cu-ATSM and FDG
sub-volumes. However, the degree of overlap varied be-
tween cases.
Our results showed that a fairly large part of the hypoxic
sub-volume as defined by 64Cu-ATSM was not included
in a boost volume based on FDG uptake with the chosen
thresholds. However, the hypoxic sub-volume did not
encompass the FDG uptake either, and it therefore
seems attractive to include both tracers in RT planning
considering their association to treatment outcome and
prognosis.
The Cu24 sub-volume was predominantly included in
the BTV consisting of FDG (FDG40 or FDG50) and
Cu3. This result suggests that the temporal variations
of 64Cu-ATSM uptake might be taken into account by
targeting a BTV consisting of FDG and Cu3 [21].
Several studies have linked FDG avidity or a high up-
take of hypoxia tracers with poor outcome [9,26-28], and
thereby confirmed the rationale for dose escalation proto-
cols. Furthermore, a recent pattern of failure analysis in
head and neck cancer patients compared FDG uptake
before RT with local recurrence and revealed a higher
recurrence density in FDG avid regions [29].
In theory, all tumor cells can be eradicated by a suffi-
ciently high radiation dose. However, dose escalation must
be balanced against the risk of early and late toxicities
of the neighboring organs. Toxicities limit the possible
escalation to large volumes, and redistribution of radi-
ation dose might address this issue [30]. Dose escalation
to potentially radioresistant areas of a tumor has proven
clinically feasible in a DPBC approach without violating
the constraints for the organs at risk [31,32]. The levels
Figure 4 Boost ratio as a function of dose prescription. Dose escalation sub-volumes for 64Cu-ATSM, FDG40 and FDG50 are shown on the left
(A + C). Intersection and union volumes of the tracers are depicted on the right (B + D). Cu-ATSM refers to dose escalation to the Cu3 sub-volume.
Intersection and union boosts also include the two FDG sub-volumes and Cu3. The solid lines represent mean values based on all 5 dogs, and the
range (80%) is illustrated in shade colors.
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of dose escalation are still not clarified, and arbitrary dose
prescriptions are often used in planning studies [6].
In this study, the average dose prescription could vary
from 66 Gy to 85 Gy. Naturally, increasing the dose pre-
scription level increases the room for dose redistribution
from the uniform or conventional homogeneous distri-
bution within the GTV. The boost ratio, R, therefore in-
creases with increasing dose prescription, P. Selecting
either FDG or 64Cu-ATSM generates more room for
dose escalation, however, a part of the biological target
might be missed. Conversely, a proper definition of the
BTV could potentially allow for dose de-escalation in
other parts of the tumor. Identification of tumor sub-
groups that are associated with a good prognosis also
enables dose de-escalation and thereby reduced toxicity
[33]. Currently, clinical trials are recruiting patients for
dose de-escalation trials in human papilloma virus-
positive head and neck cancer patients [34].
The fact that commercial treatment planning software
can be used and margins added, makes DPBC an attract-
ive strategy. However, this approach may lead to a steep
dose gradient outside the target, and since radio respon-
siveness is not binary, it can be argued that the threshold
based target volume definition is not biologically intui-
tive. Despite a relatively steep dose falloff, tumor motion
require for margins to be added on both high and low
dose volumes to ensure delivery of prescribed dose. Fur-
thermore, validations of the optimal cut-off values to use
are currently lacking [6,7].
To a certain extent, this study demonstrates some of
the drawbacks of the DPBC approach. Using this strategy
for targeting multiple biological characteristics of the
tumor in a BTV will limit the possibilities for dose escal-
ation based on the idea of a redistribution of absorbed
dose. The BTV is large and adopting that volume causes
the boost volume to become a significant part of the GTV,
allowing for only a very limited dose redistribution and
escalation to the boost region. Selecting instead the inter-
section, the volume becomes small allowing a substantial
dose escalation and, simultaneously, the variation within
the subjects becomes very large as indeed, as illustrated in
Figure 4. However, most of the PET positive volume is not
covered by a dose escalation to the intersection volume,
and it can therefore be argued that high control rates
cannot be achieved when targeting a BTV by the DPBC
strategy. The more complex DPBN approach allows a
linear relationship between dose prescription and func-
tional imaging data. A recent planning study in lung can-
cer patients compared the two strategies, and showed that
significantly higher boost doses could be achieved with
DPBN [7]. The heterogeneity of hypoxia is also a mo-
tivation for targeting multiple small sub-volumes or
using the DPBN strategy. However, the effect of dose
falloff might be a limitation for dose escalation in small
tumors, where IMRT cannot produce a dose gradient
steep enough to respect adjacent normal tissue. In some
cancers, brachytherapy therefore might be superior to
dose escalation with IMRT [35].
Under the given assumptions for dose prescription
and dose redistribution in this study, the boost volumes
appear to be either too small or too large with respect
to the total GTV. A more effective approach for dose
redistribution from the uniform or conventional dose
prescription scheme might be a DPBN strategy, where
the dose prescription can be allowed to smoothly follow
one or a weighted combination of PET tracers.
There are several limitations to this study, including a
low number of cases, varying localizations and histo-
pathological origin of the tumors. The DPBC approach
used for analysis of sub-volume overlap is based on thresh-
olding of PET images, which might influence the findings.
We used an absolute SUV of 1.4 as cut-off value based
on data from a previous study [22], and in our study this
value corresponded to 50% of SUVmax, which is a com-
monly used threshold for FDG. However, 64Cu-ATSM is
a novel PET tracer and future research still needs to
establish the most clinically relevant cut-off value that
differentiates hypoxic from non-hypoxic areas. The pos-
sible dose increase to sub-volumes display great variation
between the cases, and further studies on a more homoge-
neous group of tumors are therefore needed in order to
elucidate the possibilities for dose targeting a BTV in RT
planning. Thorough investigation of 64Cu-ATSM re-
garding distribution and uptake characteristics is also
required.
Conclusion
Based on this study of canine solid tumors FDG is not a
marker of hypoxia when using the DPBC strategy. Includ-
ing a BTV consisting of both FDG and the hypoxia tracer
64Cu-ATSM in RT planning seems attractive, as both tracers
are associated with a poor prognosis. Sub-volumes repre-
senting a large fraction of the GTV only allow a limited dose
redistribution and escalation, and targeting the BTV might
require further dose redistribution based on a weighted
combination of the PET tracers in order to obtain the
optimal tumor control.
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